The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held this year at the Hynes Convention Center in Boston Oct. 26-30, has once again brought together members of academia, pharmaceutical industry, federal regulatory agencies, and all other stakeholders in the cancer drug development space from across the globe to discuss the most up-to-date advances.
The FDA approved pembrolizumab, in immunotherapy called a checkpoint inhibitor, to treat certain patients with esophageal cancer.
A new antihormone agent has been approved to treat men with nonmetastatic prostate cancer that has stopped responding to standard antihormone treatments.
A molecularly targeted therapeutic has been approved for treating certain patients with multiple myeloma. Learn more about this recently approved therapy.
An immunotherapeutic known as a checkpoint inhibitor has been approved for the treatment of certain patients with small-cell lung cancer.
A molecularly targeted therapeutic has been approved to treat some patients with diffuse large B-cell lymphoma the most common type of non-Hodgkin lymphoma.
A combination of an immunotherapy and a molecularly targeted therapy has been approved to treat patients with advanced renal cell carcinoma, kidney cancer.
A molecularly targeted therapeutic has been approved for use in combination with fulvestrant for treating certain men and women with breast cancer.
A combination of an immunotherapy and a targeted therapeutic recently was approved by the FDA for patients advanced renal cell carcinoma (kidney cancer).
A molecularly targeted therapeutic was approved by the FDA to treating certain patients with urothelial carcinoma, the most common form of bladder cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More